TSHA - tayshagtx.com Sof foyda bo'yicha sotuv rentabelligi

Taysha Gene Therapies Inc - TSHA emitenti grafik logotipi

Sof foyda marjasi Taysha Gene Therapies (TSHA) kompaniyasining makro-barqarorligini baholashga yordam beradi, uning tadqiqotlari bozor sikllaridan mustaqil qolmoqda. Ushbu ko'rsatkichning joriy qiymati -2844.60 ni tashkil etadi, bu esa Rett sindromi terapiyasi ishlab chiqilishi uchun sarflangan kapital xarajatlar bilan bog'liqdir. Miyya patologiyalariga chalingan bolalar uchun noyob dori vositalarini yaratish kompaniyaga monopolist maqomini beradi va uzoq muddatli patent daromadlarini kafolatlaydi.

Taysha Corp (TSHA) - Sof foyda normasi 04.07.2022dan 20.11.2026gacha

Taysha (TSHA) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi statistikasi:
Kompaniyaning dastlabki tahlili:Taysha Gene Therapies
Taysha Gene Therapies Inc ishlab chiqargan mahsulot

Markaziy nerv tizimi kasalliklari uchun gen terapiyalarini ishlab chiqish ulkan investitsiyalarni talab qiladi, bu esa Taysha Gene Therapies (TSHA) uchun daromad samaradorligini monitoring qilishni muhim qiladi. Sof foydaning savdo hajmidagi nisbatini kunlik asosda baholash orqali, tijorat daromadliligining ushbu darajasi investorlarga dori vositalarini ishlab chiqishning haqiqiy xarajatlarini va hisobot sikllari orasidagi biznesning moliyaviy barqarorligi darajasini kuzatish imkonini beradi.

Raqobatdosh kompaniyalar

TEM: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha marjinallik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Sotuvning sof marjinal rentabelligi|Repligen Inc. - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi RNA|CRSP - Sof marja|GeneDx - Sof foyda bo'yicha sotuv rentabelligi|Sof foyda normasi RARE|Beam Tx - Sotuvning sof marjinal rentabelligi|SRPT - Sotuvning sof marjinal rentabelligi|TWST (Twist Bio) - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof rentabelligi TXG|Sof foyda bo'yicha sotuv rentabelligi NTLA|Stoke Therapeutics Inc (STOK) - Kompaniya sotuv marjasi|Sotuvning sof marjinal rentabelligi BLFS|Sof marja WVE (Wave Life Sciences Corp)|Sof marja Maze Therapeutics MAZE|Sof foyda normasi SION|PRME - Sof marja|QURE (uniQure) - Sotuvning sof rentabelligi|MeiraGTx Corp (MGTX) - Sof marja|Regenxbio - Sof foyda normasi|Sof marja solidbio.com|Sof marja ocugen.com OCGN|Sotuvning sof marjinal rentabelligi PACB|Benitec - Sotuvning sof rentabelligi|Sof marja Design Therapeutics DSGN|Sotuvning sof marjinal rentabelligi Rocket Pharmaceuticals RCKT|Sof foyda marjasi 4D Molecular Corp|LXEO: Sof marja|KRRO (Korro Bio, Inc) - Sof foyda bo'yicha sotuv rentabelligi|Editas Medicine (EDIT) - Sotuvning sof marjinal rentabelligi|Sof marja Silence Therapeutics Inc.|Sotuvning sof rentabelligi PRQR (proqr.com)|Sof marja Codexis Bio (CDXS)|Sotuvning sof marjinal rentabelligi sangamo.com (SGMO)|Sof marja nautilus.bio NAUT|Kompaniya sotuv marjasi Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Sotuvning sof marjinal rentabelligi|GBIO - Sotuvning sof marjinal rentabelligi|BOLD: Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi XCUR|Sof marja Imunon|Phio Pharmaceuticals - Sof foyda marjasi|Sof marja Mustang Bio, Inc. (MBIO)|Kompaniya sotuv marjasi TransCode Therapeutics, Inc.|Sof marja Bionano Genomics BNGO|Sof foyda normasi APDN|BLUE - Sof marja|Sof foyda marjasi IPA|Omega Therapeutics, Inc. (OMGA) - Sof marja|Singular Genomics Corp (OMIC) - Sotuvning sof marjinal rentabelligi|RGLS (Regulus Therapeutics, Inc.) - Sotuvning sof marjinal rentabelligi|SYRS: Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi TBIO (Telesis Bio Inc.)|Sotuvning sof marjinal rentabelligi TRACON Pharmaceuticals Inc. (TCON)|Sof marja Unity Bio UBX